Latest Security News

Canadian Phosphate (ASX: CP8) is raising up to AUD 4.85 million via a renounceable rights issue at a 22% discount, aiming to accelerate development of its newly acquired Diamond Mountain Project in Utah and advance exploration in Canada.

Venus Metals has sold its 1% Youanmi gold royalty to Franco-Nevada for $46 million, triggering plans for $35 million in special dividends and an in-specie distribution of Rox shares to shareholders.

Findi Limited surged revenue by 36% to $83 million for FY26 but posted a hefty $52.6 million net loss, weighed down by integration costs and capital delays. The company completed a major consolidation of its Indian financial infrastructure assets and secured $25 million in fresh capital to support growth and liquidity.

Sequoia Financial Group has pushed back its interim dividend payment to 29 June 2026 due to unresolved court proceedings and negotiations over the sale of its InterPrac subsidiary. The Federal Court has set a tight timetable for filings on the Share Sale Agreement status, with a potential hearing in July.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

Superloop has finalized its $165 million purchase of Lightning Broadband, adding 56,000 secured lots to its Fibre-to-the-Premises network across six Australian states and territories. The deal, funded by cash and debt, keeps net leverage low and comes with regulatory approval of a functional separation framework to support open-access wholesale services.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Sarama Resources has secured A$1.42 million through the first tranche of its A$1.5 million equity placement, with the second tranche involving director participation pending shareholder approval.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Papyrus Australia has secured a key milestone under its TBS Mining Contract by executing a board production deal with a Vietnam manufacturer, while raising $325,000 to support commercial scale-up and facility establishment.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Green Technology Metals (ASX: GT1) secured $1.87 million from its recent entitlement offer, with underwriters stepping in to cover a $2.13 million shortfall. The capital raise supports ongoing development of its Ontario lithium project.